CAD EYE® represents the culmination of Fujifilm's commitment to advancing medical imaging technology. Developed through deep learning technology at Fujifilm's global AI technology center in Tokyo, this system integrates seamlessly with the ELUXEO® Endoscopic Imaging System, delivering real-time detection capabilities to endoscopists. By leveraging AI image processing, CAD EYE® is capable of identifying lesions that may be challenging to detect with conventional methods, including flat lesions and those at the periphery of the endoscopic view.
One of the most promising features of CAD EYE® is its ability to provide immediate alerts to physicians upon detecting suspicious polyps. Through visual cues overlaid on clinical images, including a "Detection Box" and a "Visual Assist Circle," the system ensures that no potentially harmful lesions are overlooked. This functionality not only enhances the precision of colonoscopy procedures but also streamlines the workflow of endoscopists, ultimately improving patient outcomes.
Clinical studies have demonstrated the remarkable efficacy of CAD EYE® in improving adenoma detection rates during screening and surveillance colonoscopies. Compared to conventional high-definition colonoscopy, CAD EYE® detects significantly more adenomas without increasing procedure time. Moreover, it has been shown to detect colorectal neoplastic lesions at a level comparable to that of expert endoscopists, underscoring its potential to augment the skills of healthcare providers and reduce the risk of missed diagnoses.
Dr. Sravanthi Parasa, a leading gastroenterologist at Swedish Medical Center, emphasizes the transformative impact of CAD EYE® on patient care and safety. By enabling early detection of precancerous lesions and minimizing the risk of missed diagnoses, this innovative technology empowers healthcare providers to safeguard patient health and advance the fight against colorectal cancer.
With its impending commercial availability in spring 2024, CAD EYE® is poised to redefine standards of care in colorectal cancer screening and diagnosis. As Fujifilm continues to push the boundaries of medical imaging innovation, the potential for CAD EYE® to improve patient outcomes and save lives is truly profound.
Fujifilm Healthcare Americas Corporation is at the forefront of medical imaging technology, offering a comprehensive range of solutions for the detection, diagnosis, and treatment of diseases. With a commitment to innovation and clinical excellence, Fujifilm is dedicated to enhancing the lives of patients worldwide through cutting-edge medical imaging and AI initiatives.
Fujifilm Holdings Corporation, headquartered in Tokyo, is a global leader in healthcare, materials, business innovation, and imaging. With a focus on delivering value through innovation and responsible corporate citizenship, Fujifilm is dedicated to improving healthcare outcomes and enriching lives across the globe.
As we eagerly anticipate the commercial launch of CAD EYE® and the transformative impact it will have on colorectal cancer detection and prevention, Fujifilm's commitment to advancing medical imaging technology remains unwavering. Through ongoing innovation and collaboration, we are poised to usher in a new era of gastrointestinal healthcare, where early detection and intervention are paramount in the fight against colorectal cancer.
Get updates delivered to you daily. Free and customizable.
It’s essential to note our commitment to transparency:
Our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies. As a platform hosting over 100,000 pieces of content published daily, we cannot pre-vet content, but we strive to foster a dynamic environment for free expression and robust discourse through safety guardrails of human and AI moderation.
Local News
Comments / 0